Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey.


Journal

Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624

Informations de publication

Date de publication:
09 02 2023
Historique:
received: 10 11 2022
accepted: 25 01 2023
entrez: 10 2 2023
pubmed: 11 2 2023
medline: 14 2 2023
Statut: epublish

Résumé

To inform the development of updated World Health Organization (WHO) guidelines on simplified service delivery for HCV infection, a global survey was undertaken among people affected or infected by HCV. The objective of this analysis is to identify specific needs and preferences among people who inject drugs. A multi-country, anonymous, self-administered online survey conducted in 2021 was developed by Coalition PLUS and the World Hepatitis Alliance in partnership with the WHO. Preferences for test and treat locations and simplifying HCV care were collected among people affected or infected by HCV. Chi-square tests were used to compare respondents who identified with current or former injection drug users through identification with key population to other respondents who did not identify with this key population. Among 202 respondents, 62 (30.7%) identified with current/former injection drug users. Compared to other respondents, they were: older [median (IQR): 48 (36-57) vs. 39 (31-51) years, p = 0.003]; more likely to have been tested for HCV (90.2% vs. 64.3%, p = 0.001); more likely to prefer testing in a community-based centre (CBC) (55.4% vs. 33.3%, p = 0.005); or in a support centres for people who use drugs (SCPUD)(50.0% vs. 9.8%, p < 0.001). The most important considerations regarding testing locations among people identified with current/former injection drug users (compared to the other respondents) were: non-judgemental atmosphere (p < 0.001), anonymity (p = 0.018) and community worker (CW) presence (p < 0.001). People identified with current/former injection drug users were more likely to prefer to receive HCV treatment in a CBC (63.0% vs. 44.8%, p = 0.028) or in a SCPUD (46.3% vs. 9.5%, p < 0.001), compared to the other respondents. The most important considerations regarding treatment locations among people identified with current/former injection drug users were the non-stigmatising/non-judgemental approach at the site (p < 0.001) and the presence of community-friendly medical personnel or CW (p = 0.016 and 0.002), compared to the other respondents. The preferences of people identified with current/former injection drug users indicated specific needs concerning HCV services. Integration of HCV services in community-based risk reduction centres may be an important element in the development of adapted services to increase uptake and retention in HCV care among this population.

Sections du résumé

BACKGROUND
To inform the development of updated World Health Organization (WHO) guidelines on simplified service delivery for HCV infection, a global survey was undertaken among people affected or infected by HCV. The objective of this analysis is to identify specific needs and preferences among people who inject drugs.
METHODS
A multi-country, anonymous, self-administered online survey conducted in 2021 was developed by Coalition PLUS and the World Hepatitis Alliance in partnership with the WHO. Preferences for test and treat locations and simplifying HCV care were collected among people affected or infected by HCV. Chi-square tests were used to compare respondents who identified with current or former injection drug users through identification with key population to other respondents who did not identify with this key population.
RESULTS
Among 202 respondents, 62 (30.7%) identified with current/former injection drug users. Compared to other respondents, they were: older [median (IQR): 48 (36-57) vs. 39 (31-51) years, p = 0.003]; more likely to have been tested for HCV (90.2% vs. 64.3%, p = 0.001); more likely to prefer testing in a community-based centre (CBC) (55.4% vs. 33.3%, p = 0.005); or in a support centres for people who use drugs (SCPUD)(50.0% vs. 9.8%, p < 0.001). The most important considerations regarding testing locations among people identified with current/former injection drug users (compared to the other respondents) were: non-judgemental atmosphere (p < 0.001), anonymity (p = 0.018) and community worker (CW) presence (p < 0.001). People identified with current/former injection drug users were more likely to prefer to receive HCV treatment in a CBC (63.0% vs. 44.8%, p = 0.028) or in a SCPUD (46.3% vs. 9.5%, p < 0.001), compared to the other respondents. The most important considerations regarding treatment locations among people identified with current/former injection drug users were the non-stigmatising/non-judgemental approach at the site (p < 0.001) and the presence of community-friendly medical personnel or CW (p = 0.016 and 0.002), compared to the other respondents.
CONCLUSION
The preferences of people identified with current/former injection drug users indicated specific needs concerning HCV services. Integration of HCV services in community-based risk reduction centres may be an important element in the development of adapted services to increase uptake and retention in HCV care among this population.

Identifiants

pubmed: 36759855
doi: 10.1186/s12954-023-00743-8
pii: 10.1186/s12954-023-00743-8
pmc: PMC9909907
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023. The Author(s).

Références

J Viral Hepat. 2019 Jul;26(7):919-922
pubmed: 30801881
Public Health Rep. 2003 Jul-Aug;118(4):293-302
pubmed: 12815076
Subst Use Misuse. 2017 Sep 19;52(11):1420-1428
pubmed: 28430013
Int J Drug Policy. 2021 Oct;96:103354
pubmed: 34247900
Int J Drug Policy. 2021 Oct;96:103469
pubmed: 34610884
BMC Med. 2017 Nov 20;15(1):204
pubmed: 29151365
Int J Drug Policy. 2022 Apr;102:103580
pubmed: 35074607
Int J Equity Health. 2017 May 12;16(1):78
pubmed: 28499378
BMC Health Serv Res. 2014 Mar 03;14:99
pubmed: 24589335
BMC Infect Dis. 2022 May 31;22(1):510
pubmed: 35641908
Transcult Psychiatry. 2012 Apr;49(2):165-84
pubmed: 22508635
Int J Drug Policy. 2019 Oct;72:195-198
pubmed: 30981613
J Subst Abuse Treat. 2020 Jul;114:108025
pubmed: 32527512
Liver Int. 2021 Nov;41(11):2578-2589
pubmed: 34153155
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327
pubmed: 28404202
Drug Alcohol Depend. 2019 May 1;198:80-86
pubmed: 30884432
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
J Viral Hepat. 2014 May;21 Suppl 1:5-33
pubmed: 24713004
Hepatol Med Policy. 2016 Jun 30;1:2
pubmed: 30288305
Clin Psychol Psychother. 2013 Sep-Oct;20(5):434-46
pubmed: 22371333
Drug Alcohol Depend. 2014 Nov 1;144:259-64
pubmed: 25307745
J Intern Med. 2019 Nov;286(5):503-525
pubmed: 31472002
Int J Drug Policy. 2015 Dec;26(12):1198-206
pubmed: 26118796
BMC Infect Dis. 2021 Jun 26;21(1):609
pubmed: 34171990
Public Health. 2021 Jun;195:42-50
pubmed: 34051674
BMJ Open. 2020 Nov 18;10(11):e039234
pubmed: 33208326
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051
pubmed: 29633559
Med Care Res Rev. 2000;57 Suppl 1:181-217
pubmed: 11092163
BMC Infect Dis. 2022 Sep 15;22(1):738
pubmed: 36109704
Can J Infect Dis Med Microbiol. 2016;2016:4385643
pubmed: 27471521
Int J Drug Policy. 2019 Oct;72:146-159
pubmed: 31147142
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444
pubmed: 30981685
Int J Drug Policy. 2019 Mar;65:41-49
pubmed: 30594080
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62
pubmed: 23817321
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Int J Drug Policy. 2021 Oct;96:103247
pubmed: 33853727
Harm Reduct J. 2019 Feb 11;16(1):14
pubmed: 30744628
Harm Reduct J. 2022 Aug 24;19(1):95
pubmed: 36002850

Auteurs

M Di Ciaccio (M)

Community-Based Research Laboratory, Coalition PLUS, Pantin, France. mdiciaccio@coalitionplus.org.

V Villes (V)

Community-Based Research Laboratory, Coalition PLUS, Pantin, France.

C Perfect (C)

Advocacy Department, Coalition PLUS, Pantin, France.

J L El Kaim (JL)

Advocacy Department, Coalition PLUS, Pantin, France.

M Donatelli (M)

Advocacy Department, Coalition PLUS, Pantin, France.

C James (C)

World Hepatitis Alliance, London, UK.

P Easterbrook (P)

Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.

R M Delabre (RM)

Community-Based Research Laboratory, Coalition PLUS, Pantin, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH